Type 2 Diabetes Mellitus
Conditions
Brief summary
It is well known that Long-term hyperglycemia (also known as glucose toxicity) contribute to impairment in islet β-cell function and development of insulin resistance. A growing body of evidence also indicates that this impairment inβ-cell function and insulin action could be restored after hyperglycemia is corrected by short-term intensive insulin therapy. In this study, we are determined to use the golden standard of insulin sensitivity evaluation in vivo-hyperinsulinemia euglycemic glucose clamp-to estimate insulin resistance improvement in patients before and after intensive insulin therapy, investigate first phase insulin secretion to evaluate β-cell function, examine the changes in insulin resistance and insulin secretion resulting from normalization of plasma glucose levels in both lean and obese patients by insulin pump therapy.
Interventions
DRUGinsulin aspart
Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
Sponsors
Li Guangwei
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age: 25 to 60 years old * Duration of diabetes: newly diagnosed type 2 diabetes (duration of diabetes less than 1 year) and haven't taken any antidiabetic medication. * Fasting blood glucose is above 11.0mmol/L. * Half of the patients with BMI below 24 and the other half with BMI above 24.
Exclusion criteria
* type 1 diabetes mellitus * type 2 diabetes patients with intercurrent illness (ketoacidosis, infection or any other acute stress) * Presence of auto-immune disease, hepatic or renal disease or any concomitant disease is not allowed. * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC75-120 of Glucose Infusion Rate (GIR) | after 2 weeks insulin pump intensive therapy, and one-year follow-up after termination of treatments |
Secondary
| Measure | Time frame |
|---|---|
| AUC0-10 of Acute Insulin Response (AIR) during IVGTT | after 2 weeks insulin pump intensive therapy, and one-year follow-up after termination of treatments |
Outcome results
None listed